Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessMoneycontrol Research

Dhanuka Agritech Q1: Soft quarter as monsoon clouds the show

July 23, 2019 / 05:23 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Ruchi Agrawal

Moneycontrol Research


Highlights


  • Delay in monsoon and sowing impacts June sales

  • High raw material costs eat up profit margin

  • Volume growth remains muted, price hike drives revenue

  • Controlled sales overhead positive for EBIT

  • New product launches to drive growth

Dhanuka Agritech (DHAN) reported another subdued quarter with continued pressure on margins. Delay in monsoon impacted the June sales for the company, which is expected to spill over to the current quarter.

dhanuka1

Key positives

- Earnings before interest, tax, depreciation and amortisation (EBITDA) margin improved 185 basis points (bps) year-on-year (YoY) due to the controlled sales expenses and lower overheads.

Key negatives

-Delay in the onset of monsoon and sowing impacted the agrochemical business in June due to which the topline growth for the company remained largely muted at 3 percent YoY.

-While volume growth remained largely tepid, the marginal uptick in revenue was driven by its price increase in order to partially pass on the uptick in raw material costs.

- High cost inventory coupled with increase in competition led to a 110 basis points (bps) contraction in the gross margin.

Other comments

-Dhanuka has six new products which are to be launched this year, of which three have already been launched. Traction from these new launches is expected to support top line in coming quarters. However, gains from the product mix improvement have been negated by higher technical prices and lower demand (due to deficient monsoon).

-The company is revamping its marketing network to accelerate overall business growth. It is focusing more on high revenue generating customers via its Kohinoor scheme and also weeding out uncompetitive dealers.

-Dhanuka Laboratories, a promoter group entity, has successfully bid for Orchid Pharma through the National Company Law Tribunal (NCLT) auction for an estimated Rs 600 crore. The management has guided that promoters will pledge a part of its stake in the company to fund this acquisition.

Outlook

The stock has corrected 39 percent from its 52-week high. After the correction, the stock is trading at an FY20 estimated price-to-earnings of 14.7 times.

dhanuka2


While the improving product mix is a positive for the long-term growth for the company, the high raw material prices and unpredictable monsoon are impacting the performance negatively. Monsoon performance in the current quarter (Q2) would be something to watch out for.Follow @Ruchiagrawal

For more research articles, visit our Moneycontrol Research Page

Ruchi Agrawal

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347